Episurf Medical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Pal Ryfors

Chief Executive Officer (CEO)

SEK 4.5m

Compensación total

Porcentaje del salario del CEO	84.4%
Permanencia del CEO	7yrs
Participación del CEO	0.5%
Permanencia media de la dirección	6yrs
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

Recent updates

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

We Think Some Shareholders May Hesitate To Increase Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation

May 03

Pål Ryfors Is The CEO & Sales Director of Episurf Medical AB (publ) (STO:EPIS B) And They Just Picked Up 2.3% More Shares

Feb 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pal Ryfors en comparación con los beneficios de Episurf Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-SEK 92m
Dec 31 2023	SEK 5m	SEK 4m	-SEK 95m
Sep 30 2023	n/a	n/a	-SEK 97m
Jun 30 2023	n/a	n/a	-SEK 94m
Mar 31 2023	n/a	n/a	-SEK 84m
Dec 31 2022	SEK 5m	SEK 4m	-SEK 77m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 4m	SEK 3m	-SEK 69m
Sep 30 2021	n/a	n/a	-SEK 67m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 63m
Dec 31 2020	SEK 4m	SEK 3m	-SEK 64m
Sep 30 2020	n/a	n/a	-SEK 66m
Jun 30 2020	n/a	n/a	-SEK 69m
Mar 31 2020	n/a	n/a	-SEK 73m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 70m
Sep 30 2019	n/a	n/a	-SEK 66m
Jun 30 2019	n/a	n/a	-SEK 62m
Mar 31 2019	n/a	n/a	-SEK 59m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 58m
Sep 30 2018	n/a	n/a	-SEK 58m
Jun 30 2018	n/a	n/a	-SEK 59m
Mar 31 2018	n/a	n/a	-SEK 55m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 61m

Compensación vs. Mercado: La compensación total de Pal($USD431.23K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD257.80K).

Compensación vs. Ingresos: La compensación de Pal ha sido consistente con los resultados de la empresa en el último año.

CEO

Pal Ryfors (41 yo)

7yrs

Permanencia

SEK 4,500,000

Compensación

Mr. Pal Ryfors is Independent Director of Vivesto AB since May 2022. He serves as Chief Executive Officer of Episurf Medical AB (publ) since June 2, 2017 and served as its Acting Sales Director since 2021....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pal Ryfors	Chief Executive Officer	7yrs	SEK 4.50m	0.46% SEK 661.5k
Veronica Wallin	Chief Financial Officer	7yrs	sin datos	0.017% SEK 24.7k
Katarina Flodström	Chief Operating Officer	5yrs	sin datos	0.016% SEK 22.7k
Fredrik Zetterberg	Marketing Director	7.4yrs	sin datos	0.0041% SEK 5.8k
Ylva Bonde	Head of QA & RA	less than a year	sin datos	sin datos
Patrick Jamnik	President of Episurf Medical Inc	2.8yrs	sin datos	0.041% SEK 59.1k

6.0yrs

Permanencia media

43yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EPIS B es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ulf Grunander	Independent Chairman of the Board	3.1yrs	SEK 400.00k	0.058% SEK 84.0k
Annette Rampe	Independent Director	3.1yrs	SEK 200.00k	0.037% SEK 52.9k
Laura Shunk	Independent Director	7.4yrs	SEK 200.00k	0.12% SEK 176.4k
Leif Ryd	Member of Clinical Advisory Board & Director	15.4yrs	SEK 800.00k	0.090% SEK 128.7k
Tim Spalding	Member of Clinical Advisory Board	8.6yrs	sin datos	sin datos
Johannes Holz	Member of Clinical Advisory Board	8.6yrs	sin datos	sin datos
Mats Brittberg	Member of Clinical Advisory Board	8.6yrs	sin datos	sin datos
Karl Eriksson	Member of Clinical Advisory Board	8.6yrs	sin datos	sin datos
Christian Krueger	Independent Director	8.1yrs	SEK 200.00k	0.046% SEK 66.2k
Adam Mitchell	Member of Clinical Advisory Board	7.3yrs	sin datos	sin datos
C. van Dijk	Member of Clinical Advisory Board	5.2yrs	sin datos	sin datos
Joao Mendes	Member of Clinical Advisory Board	no data	sin datos	sin datos

8.1yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de EPIS B se considera experimentada (8.1 años de antigüedad promedio).

Episurf Medical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently bought kr129k worth of stock

Insufficient new directors

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Chief Executive Officer recently bought kr660k worth of stock

Recent updates

New major risk - Shareholder dilution

Episurf Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 90.158983 million.

Independent Director recently bought kr129k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 14%

First quarter 2024 earnings released: kr0.077 loss per share (vs kr0.087 loss in 1Q 2023)

New major risk - Market cap size

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Here's Why Episurf Medical (STO:EPIS B) Must Use Its Cash Wisely

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Episurf Medical AB (Publ) Receives Four Additional Patent Approval Notification

Is Episurf Medical (STO:EPIS B) In A Good Position To Invest In Growth?

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Third quarter 2023 earnings released

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Medical Announces 510(k) Submission for Big Toe Implant

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress

Episurf Medical Announces Prospective Episealer Talus Clinical Study

Episurf Medical AB (publ) Announces First Commercial Case in the US Has Been Scheduled for Surgery

Second quarter 2023 earnings released

Chief Executive Officer recently bought kr660k worth of stock

Will Episurf Medical (STO:EPIS B) Spend Its Cash Wisely?

First quarter 2023 earnings released

Chief Executive Officer recently bought kr72k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Episurf Medical AB (publ), Annual General Meeting, May 04, 2023

Episurf Medical AB (publ) Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors

Episurf Medical AB (Publ) Receives Notice of Allowance from the United States Patent and Trademark Office

Episurf Medical AB (publ) Receives FDA 510(k) clearance for Episealer® Patellofemoral System

Consensus revenue estimates fall by 20%

Third quarter 2022 earnings released

Price target decreased to kr5.65

Episurf Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 09, 2024

Episurf Medical Announces That the Episealer® Knee Technology and Clinical Results

Episurf Medical AB (Publ) Appoints Nomination Committee

We're Not Very Worried About Episurf Medical's (STO:EPIS B) Cash Burn Rate

Episurf Medical AB (Publ) Provides Update on 510(K) Application to FDA for the Episealer Patellofemoral System

Episurf Medical Announces New U.S. Patent Approval for Episurf Medical

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong for Episurf Medical

Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress

Consensus forecasts updated

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong

Second quarter 2022 earnings released

Episurf Medical AB (Publ) Announces First Surgery in India with the Knee Implant Episealer® Has Been Scheduled

First quarter 2022 earnings: Revenues miss analyst expectations

Price target decreased to kr5.65

Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System

New European Patent Approves for Episurf Medical

Episurf Medical AB (Publ) Announces the Initiation of a Prospective Investigator-Initiated Study with 2 Years Follow-Up of 25 Episealer Talus Patients

First Indian Patent Approval for Episurf Medical

Episurf Medical Receives Reimbursement Coverage for Episealer Talus in Belgium

Episurf Medical AB’s Implants Receive National Regulatory Approval in Hong Kong

Consensus revenue estimates fall by 34%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

The European Patent Office Approves European Patent for Episurf Medical

the European Patent Office EPO Announces Its Intention to Grant Another European Patent for Episurf Medical AB (publ)

Episurf Medical Submits 510(K) Application for Episealer® Patellofemoral System

Board Member recently bought kr798k worth of stock

CEO & Acting Sales Director recently bought kr185k worth of stock

Chief Financial Officer recently bought kr51k worth of stock

Third quarter 2021 earnings released

Episurf Medical (STO:EPIS B) Is In A Good Position To Deliver On Growth Plans

Independent Director recently bought kr98k worth of stock

Episurf Medical AB (Publ) Announces Results from Multicentre Study